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Objectives The purpose of this study was to test the ability of insulin-like growth factor (IGF)-1/hepatocyte growth factor
(HGF) to activate resident endogenous porcine cardiac stem/progenitor cells (epCSCs) and to promote myocar-
dial repair through a clinically applicable intracoronary injection protocol in a pig model of myocardial infarction
(MI) relevant to human disease.
Background In rodents, cardiac stem/progenitor cell (CSC) transplantation as well as in situ activation through intramyocardial
injection of specific growth factors has been shown to result in myocardial regeneration after acute myocardial
infarction (AMI).
Methods Acute MI was induced in pigs by a 60-min percutaneous transluminal coronary angiography left anterior de-
scending artery occlusion. The IGF-1 and HGF were co-administered through the infarct-related artery in a single
dose (ranging from 0.5 to 2 g HGF and 2 to 8 g IGF-1) 30 min after coronary reperfusion. Pigs were sacrificed
21 days later for dose-response relationship evaluation by immunohistopathology or 2 months later for cardiac
function evaluation by cardiac magnetic resonance imaging.
Results The IGF-1/HGF activated c-kit positive–CD45 negative epCSCs and increased their myogenic differentiation in vitro.
The IGF-1/HGF, in a dose-dependent manner, improved cardiomyocyte survival, and reduced fibrosis and cardiomyo-
cyte reactive hypertrophy. It significantly increased c-kit positive–CD45 negative epCSC number and fostered the gen-
eration of new myocardium (myocytes and microvasculature) in infarcted and peri-infarct/border regions at 21 and
60 days after AMI. The IGF-1/HGF reduced infarct size and improved left ventricular function at 2 months after AMI.
Conclusions In an animal model of AMI relevant to the human disease, intracoronary administration of IGF-1/HGF is a practical
and effective strategy to reduce pathological cardiac remodeling, induce myocardial regeneration, and improve ven-
tricular function. (J Am Coll Cardiol 2011;58:977–86) © 2011 by the American College of Cardiology Foundation
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CSC Activation by IGF-1/HGF for Heart Regeneration August 23, 2011:977–86The presence of endogenous res-
ident cardiac stem and progeni-
tor cells (eCSCs) in the adult
mammalian heart of different
species, including human (1,2),
supports the notion that the
adult myocardium has an intrin-
sic regenerative capacity, which
could be exploited to produce
meaningful myocardial regenera-
tion (3–6).
Data from mice and dogs
show that the regenerative re-
sponse of eCSCs to a ischemic
insult can be enhanced in situ by
administration of growth factors
(7,8). Nevertheless, before such
protocols can be clinically tested,
they need to be validated in a
large-animal model that closely
mimics the human heart using a
growth factor dose and method of
administration compatible with
clinical application. Swine, because
of similarities to ours in organ size,
coronary anatomy, immunology,
and physiology, stands up as the most attractive model for
pre-clinical protocols of eCSC activation for myocardial
regeneration.
Here, we show that the adult pig myocardium harbors
c-kit positive (c-kitpos) CD45 negative (CD45neg) eCSCs,
hich show rapid activation and robust cardiomyogenic
ifferentiation when stimulated by insulin-like growth fac-
or (IGF)-1 and/or hepatocyte growth factor (HGF) in
itro. Small amounts of IGF-1 and HGF administered to
he damaged porcine myocardium through the coronary
irculation after acute myocardial infarction (AMI), in a linear
ose/effect relationship, salvages a significant portion of the
yocardium at risk, produces a robust activation of the resident
CSC pool and regenerates most myocytes and microvascula-
ure lost by the ischemic insult. At 2 months after myocardial
nfarction (MI), this treatment results in improved left ventric-
lar (LV) function and reduced infarct size.
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Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BrdU  bromodeoxyuridine
CD45neg  CD45 negative
c-kitpos  c-kit positive
cMRI  cardiac magnetic
resonance imaging
CSC  cardiac stem/
progenitor cell
CTRL  control
eCSC  endogenous
resident cardiac stem/
progenitor cells
epCSC  endogenous
porcine cardiac stem/
progenitor cell
HGF  hepatocyte growth
factor
IGF  insulin-like growth
factor
LV  left ventricular
MI  myocardial infarctionManuscript received April 20, 2011; revised manuscript received May 20, 2011,
accepted May 24, 2011.ethods
ee the Online Appendix for a complete description of
ethods.
esults
orcine resident c-kitposCD45neg cardiac cells are multi-
potent stem/progenitor cells. Small cells positive for c-kit
(c-kitpos) and negative for blood-cell lineage markers (i.e.,
CD45), Linneg, are ubiquitous in the adult porcine myocar-
ium, with higher density in the atria and the ventricular
pex (Online Fig. 1).
The c-kitpos cardiac cells constituted 9 2% and 4 2% of
he starting myocyte-depleted cardiac small cell population
rom atria and LV, respectively (Fig. 1A). Moreover, 75 
2% and 50 8% of these c-kitpos cells from the atria and the
left ventricle, respectively, also expressed CD45 (Figs. 1B and
1C), which, when co-expressed with c-kit, identifies resident
cardiac mast cells (9). Thus, using negative (CD45) and
positive (c-kit) sorting by magnetic activated cell sorting
technology, we obtained 95% enriched c-kitpos cardiac cells,
epleted of tryptasepos and CD45pos mast cells (Figs. 1D and
E), and endothelial/hematopoietic CD34pos progenitors
(Online Fig. 2). A fraction of c-kitposCD45neg cardiac cells
xpressed the mesenchymal marker, CD90 (38  6%) and
adhesion molecule/cardiac progenitor marker, CD166 (74 
11%) (Fig. 1E). Porcine c-kitposCD45neg cardiac cells were
egative for a panel of CD markers specific for other hema-
opoietic, mesenchymal, and endothelial cell lineages (Online
ig. 2). Freshly isolated c-kitposCD45neg cells expressed
Oct3/4 (3  1%) (Fig. 1F to 1H), SSEA-4 (11  2%)
Fig. 1F), SSEA-3 (10  3%), Nanog (9  3%), Telomerase
58  8%), Bmi-1 (59  11%), Flk-1 (46  5%), Gata-4
49  7%), Nkx2.5 (29  10%), and Isl-1 (1  1%).
The c-kitposCD45neg cells from atria, ventricles, and apex
exhibited 20% clonal efficiency, independently of their
hamber of origin (Online Fig. 3). Three randomly picked
lones each from atria-, ventricle-, and apex-derived cells
ere further expanded. These clones had a 22 h doubling
ime. They have been propagated for 65 passages and
erially subcloned every 10 passages without reaching
rowth arrest, senescence, or showing any detectable chro-
osomal alterations (Online Fig. 4). Cloned cells showed
ositivity for c-kit (90 8%), Oct3/4 (62 11%), SSEA-3
65  10%), SSEA-4 (59  14%), Nanog (46  5%),
telomerase (81 10%), Bmi-1 (70 14%), Flk-1 (86 9%),
Gata-4 (60  11%), Nkx2.5 (52  8%) and Isl-1 (8  6%)
(Figs. 1G and 1H, Online Figs. 3 and 5), indicating higher
lonal efficiency of cells expressing multipotency genes.
Cloned c-kitposCD45neg cardiac cells grew in suspension
and generated cardiospheres (1,2). Cardiospheres placed in
differentiation medium attached, and cells spread out from
the sphere (Online Fig. 3), differentiating into myocytes
(27  4%), endothelial (10  6%), and smooth muscle cells
(34  5%) (Online Fig. 3). These results show that porcine
resident c-kitposCD45neg cardiac cells (hereafter identified
979JACC Vol. 58, No. 9, 2011 Ellison et al.
August 23, 2011:977–86 CSC Activation by IGF-1/HGF for Heart RegenerationFigure 1 Phenotype of Porcine c-kitposCD45neg Cardiac Stem/Progenitor Cells
(A) Florescence activated cell sorting (FACS) analysis of c-kitpos CD45pos cells within the myocyte-depleted cardiac small cells from the atria and left ventricle (LV).
(B, C) FACS analysis of c-kitpos magnetic activated cell sorting (MACS)-sorted cells from right atria and LV distinguishes CD45 positive and negative fractions. (D)
A significant fraction of freshly isolated porcine c-kitpos (green) cardiac cells express tryptase (red; a) but when depleted of CD45pos, cells are negative for tryptase (b).
Bar  20 m. (E) Phenotype of c-kitposCD45neg cells obtained using MACS sorting. (F) Oct-4 expression (red; a) and SSEA-4 expression (green; b) in freshly isolated
ckitposCD45neg cardiac cells. Nuclei stained by 4’,6-diamidino-2-phenylindole (DAPI) in blue. Bar  50 m. (G, H) Bar graph and representative gel showing stemness
and cardiac gene transcripts in freshly isolated and cloned endogenous porcine cardiac stem/progenitor cell (epCSCs). *p  0.05 versus freshly isolated epCSCs.
DNA  deoxyribonucleic acid; FITC  fluorescein isothiocyanate; mRNA  messenger ribonucleic acid; PE  phycoerythrin; qRT-PCR  quantitative reverse transcription-
polymerase chain reaction.
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CSC Activation by IGF-1/HGF for Heart Regeneration August 23, 2011:977–86as endogenous porcine CSCs [epCSCs]) have true stem/
progenitor cell characteristics (2).
The epCSCs express intact IGF-1/HGF signaling pathways
that modulate their activation and differentiation in vitro.
The epCSCs express IGF-1 and HGF (known as c-met)
receptors (Online Fig. 3). When grown in culture, freshly
isolated and cloned c-kitposCD45neg epCSCs respond to
stimulation with human recombinant IGF-1 and human
recombinant HGF with proliferation, migration, and activa-
tion of specific downstream effector pathways (Online Fig. 6).
When IGF-1/HGF were separately added to epCSCs,
IGF-1 had no effect on myogenic differentiation, as mea-
sured by the number of Nkx2.5 and cardiac troponin I
positive cells (Figs. 2A to 2D). In contrast, HGF increased
significantly the number of these cells (Figs. 2A to 2D). The
combination of the 2 factors did not increase myogenic
differentiation over HGF alone (Figs. 2A to 2D). Yet,
neither factor alone or in combination was able to induce
epCSC differentiation into beating myocytes. However,
co-culture with adult rat ventricular myocytes induced
epCSCs (tagged with green fluorescent protein lentiviral
construct [GFPpos]) to synchronized beating (Online Video 1).
The HGF was a stronger inducer of functional cardiomyogenic
differentiation than IGF-1, while the combination of both
growth factors significantly improved the effects of each alone
(Figs. 2E and 2F). These data suggest that HGF is able to
prompt epCSC cardiomyogenic commitment per se without
inducing cell contraction. Together, IGF-1 and HGF
stimulate a paracrine response in adult myocytes that in-
duces functional cardiomyogenic maturation of differenti-
ating epCSCs in vitro.
Intracoronary IGF-1/HGF injection after AMI preserves
the organization of the infarcted tissue and improves
cardiomyocyte survival. The IGF-1/HGF were admin-
istered to female juvenile White pigs (22 3 kg) after AMI
produced by 1 h of total balloon occlusion of the left
anterior descending coronary artery below the origin of
the first diagonal branch, followed by 30 min reperfusion
(10). Different doses of IGF-1/HGF, identified as 1,
2, and 4 dose (0.5/2 g, 1/4 g, and 2/8 g,
respectively) (see Online Fig. 7) were administered in 15
ml of phosphate-buffered saline over 15 min at a rate of
1 ml/min with 1 min reperfusion every 5 min. The
control group pigs (CTRL) were submitted to the iden-
tical protocol but received saline alone. To track myocar-
dial cell regeneration, animals were administered bro-
modeoxyuridine (BrdU) through an implanted osmotic
pump for 14 days.
There was no statistical difference in the infarcted area at
the time of sacrifice, between the IGF-1/HGF-treated and
the CTRL group (23  2%, 21  3%, 20  3% in
IGF-1/HGF 1, 2, and 4, respectively, vs. 21  3% in
CTRL) 21 days after AMI. However, histological analysis
revealed islands of survived myocardial tissue distributed
among the fibrotic infarcted zone that were more abundant
in the IGF-1/HGF treated than in the CTRL infarctedmyocardium (Figs. 2G and 2H). These islands consisted of
large BrdU-negative cardiomyocytes, a phenotype that,
together with their mature, even hypertrophic nature con-
firmed their survival as pre-infarct myocytes (Fig. 2I).
Compared with CTRL, the IGF-1/HGF-treated hearts, in
a dose-dependent manner, had significantly less fibrotic
tissue in the infarct region (Figs. 2J to 2L). Additionally,
IGF-1/HGF reduced myocyte apoptosis and hypertrophy
in the peri-infarct/border zone in a dose-dependent manner
(Figs. 2M to 2O). These findings indicate that early
IGF-1/HGF administration after AMI rescues myocytes at
risk and improves myocardial remodeling in pigs.
Intracoronary IGF-1/HGF administration after AMI
activates epCSCs. In healthy and post-AMI hearts,90%
of c-kitpos epCSCs express IGF-1 and c-met (HGF) recep-
tors (Figs. 3A and 3B). Accordingly, 21 days after AMI,
IGF-1/HGF-treated infarcted hearts showed a significant
increase of c-kitposCD45neg epCSCs in the border region
nd even higher in the infarcted area (Figs. 3C and 3D).
hese cells are CD45neg and tryptaseneg and were clearly
distinguishable from resident c-kitposCD45pos cardiac mast
cells (Fig. 1D).
That the increase in c-kitposCD45neg epCSCs is the
result of IGF-1/HGF administration was confirmed by its
direct correlation to the IGF-1/HGF-dose administered
(Fig. 3D). At the highest dose, the number of epCSCs in
the infarcted area is more than 6-fold greater than in the
CTRL hearts (Fig. 3D, Table 1). Most epCSCs were BrdU
positive, a fixture that documents their birth after AMI
(Fig. 3E). Many epCSCs expressed either transcription
factor Nkx-2.5, Ets-1, or Gata6, indicative of their com-
mitment to the myocyte, endothelial, and smooth muscle
lineage, respectively (Figs. 3F to 3I). The number of
committed myogenic progenitors (c-kitposNkx2.5pos cells)
significantly increased in the infarct and border regions of
the treated hearts in a dose-dependent manner (Fig. 3G,
Table 1).
IGF-1/HGF administration produces robust myocardial
cell regeneration after AMI. As expected from the in-
crease in epCSCs and committed myocyte progenitors,
IGF-1/HGF-treated hearts harbored a large population of
very small, newly formed BrdUpos and still-proliferating
(Ki67pos) myocytes in the infarct and border regions (Figs. 4A
o 4F). Furthermore, some were in mitosis and cytokinesis,
onfirming their immature nature (Fig. 4G). Newly formed
rdUpos myocytes were also present in the border region of the
TRL pigs. However, their number was less than one-fifth of
hose in IGF-1/HGF 1 treated hearts, and they were
ractically absent in the infarct zone (Figs. 4H and 4I, Online
ig. 8, Table 1).
There was a direct correlation between the number of
mall BrdUpos/Ki67pos newly formed myocytes and IGF-1/
HGF-dose (Fig. 4H and 4I, Table 1). The BrdUpos myo-
cytes were organized as clusters of regenerating bands in the
infarct zone, which were more organized and compacted
with increasing IGF-1/HGF dose (Fig. 4A and 4B).
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August 23, 2011:977–86 CSC Activation by IGF-1/HGF for Heart RegenerationFigure 2 Effects of IGF-1/HGF on epCSC Myogenic Differentiation In Vitro and on Myocardial Cell Remodeling After AMI In Vivo
(A, B) Number and representative staining of Nkx-2.5 (green) positive myocyte progenitor endogenous porcine cardiac stem/progenitor cells (epCSCs) upon insulin-like
growth factor (IGF)-1/hepatocyte growth factor (HGF) treatment (*p  0.05 vs. control [CTRL] and IGF-1). Bar  50 m. (C, D) Number and representative staining of
cardiac troponin I (cTnI) positive epCSCs (cTnI; red) upon IGF-1/HGF treatment (*p  0.05 vs. CTRL and IGF-1). Bar  50 m. (E, F) Number and representative staining
of GFPpos (green) epCSC-derived beating cardiomyocytes (cTnI; red), when co-cultured with adult rat ventricular myocytes upon IGF-1/HGF treatment (*p  0.05 vs. CTRL;
#p  0.05 vs. IGF-1; †p  0.05 vs. all). Yellow arrows point to newly formed contractile GFPpos epCSC-derived myocytes, while small white arrows point to very immature GFP-
pos epCSC-derived small myocyte precursors. Bar  20 m. (G, H) Islands of survived myocardial tissue in the infarct zone of 4 IGF-1/HGF-treated pigs (G; arrows), which
were infrequent and less defined in structure in the CTRL (H). Bar  50 m. (I) Surviving, mature, bromodeoxyuridine (BrdU) negative cardiomyocytes (cTnI; red) constituted
these survived myocardial islands. Bar  50 m. (J, K) Representative fibrotic tissue (sirius red staining) in the infarct zone, in 4 IGF-1/HGF-treated (J) and CTRL (K) pig
hearts. Bar  500 m. (L) Percentage area fraction of fibrosis in the infarct zone. *p  0.05 versus CTRL; †p  0.05 versus IGF-1/HGF 1. (M) Apoptotic myocytes
(casapse-3, brown; arrowheads) in the peri-infarct/border zone of a CTRL pig heart. Bar  50 m. (N) Cumulative data on myocyte apoptosis in the peri-infarct/border zone.
*p  0.05 versus CTRL; †p  0.05 versus IGF-1/HGF 1; ‡p  0.05 versus IGF-1/HGF 2. (O) Cumulative data on myocyte hypertrophy. *p  0.05 versus CTRL; †p  0.05
versus IGF-1/HGF 1. All data are mean  SD, n  5, 4, 5, and 4 for CTRL, IGF-1/HGF 1, 2, and 4, respectively. AMI  acute myocardial infarction. See Online Video 1.
e
4
i
w
T
B
982 Ellison et al. JACC Vol. 58, No. 9, 2011
CSC Activation by IGF-1/HGF for Heart Regeneration August 23, 2011:977–86In association with the appearance of epCSCs committed
to the vascular lineage in response to IGF-1/HGF (Figs. 3H
and 3I), newly formed BrdU-positive vascular structures were
vident in the border and infarcted myocardium (Figs. 4J and
K, Online Fig. 9). The IGF-1/HGF-treated hearts displayed
ncreased number of capillaries in the infarct zone, compared
ith CTRL, and this response was dose dependent (Fig. 4L,
able 1, Online Fig. 9). Interestingly, new microvessels and
rdUpos myocytes in regenerating bands were most evident
Figure 3 IGF-1/HGF Intracoronary Administration After AMI Ac
(A, B) The c-kitpos endogenous porcine cardiac stem/progenitor cells (epCSCs) (g
in vivo. (C) A large cluster of c-kitpos (green) epCSCs in the infarct zone of an IGF-
in the border (open bars) and infarcted (solid bars) regions of IGF-1/HGF-treated a
positive epCSCs in the IGF-1/HGF 4 treated pig heart. (F) The c-kitpos epCSCs e
tor cells. (G) Number of c-kitposNkx2.5pos myocyte progenitor cells. (H, I) Some c-k
indicative of smooth muscle and endothelial cell differentiation, respectively. Nucl
4, 5, and 4 for CTRL, IGF-1/HGF 1, 2, and 4, respectively. *p  0.05 versus
bars  20 m. AMI  acute myocardial infarction.around survived myocardium islands within the infarct (OnlineFig. 9). This organization, together with the in vitro data
(Figs. 2A to 2F), suggests that adult spared myocytes produce
cardiopoietic factors (11) acting on the epCSCs.
It should be stressed that, at 21 days after MI, the
regenerated myocytes in the infarct were still immature, as
demonstrated by their size which, on average, was signifi-
cantly smaller than normal adult porcine myocytes (Table 1).
Furthermore, many of these regenerating myocytes were still
cycling, as demonstrated by the expression of Ki67 (Fig. 4). In
s epCSCs Driving Their Cardiac Commitment
xpress (A) insulin-like growth factor (IGF)-1 (red) and (B) c-met (red) receptors
atocyte growth factor (HGF) 4 treated pig heart. (D) Number of c-kitpos epCSCs
ntrol (CTRL) pigs. (E) Newly generated c-kitpos, bromodeoxyuridine (BrdU) (red)
ed the cardiac transcription factor, Nkx2.5 (red), representing myocyte progeni-
pCSCs expressed the transcription factors, (H) Gata-6 (red) and (I) Ets-1 (red),
stained by 4’,6-diamidino-2-phenylindole (DAPI). All data are mean  SD; n  5,
, †p  0.05 versus IGF-1/HGF 1; ‡p  0.05 versus IGF-1/HGF 2. All scaletivate
reen) e
1/hep
nd co
xpress
itpos e
ei are
CTRLagreement with the suggested cardiopoietic factors secreted by
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August 23, 2011:977–86 CSC Activation by IGF-1/HGF for Heart Regenerationmature myocytes, those newly formed myocytes in contact or
close proximity with mature ones (i.e., in the border zone) were
significantly larger than those in the middle of the scar with
no proximity to spared myocytes (Fig. 4, Online Fig. 9). Also,
IGF-1/HGF enhanced myocyte maturation, as shown by the
increased average size of BrdUpos myocytes with increasing
ose (Table 1). However, despite this robust regeneration of
yocyte number, the treated hearts still had a severe myocyte-
ass deficit due to the significantly smaller size of the regen-
rated myocytes compared with those lost by the AMI.
GF-1/HGF treatment improves cardiac function after
MI. To test the effects on cardiac function after AMI,
GF-1/HGF at a 4 dose or saline (CTRL) was given by
ntracoronary administration to additional pigs. Cardiac
agnetic resonance imaging (cMRI) was performed before
oronary occlusion, at 72 h, at 1 month and before sacrifice,
nd at 2 months after AMI (Online Fig. 7).
Intracoronary administration of a 4 dose of IGF-1/
GF (n  5) maintained the favorable histological effects
n myocardial repair also at 2 months after MI (Online
ig. 10). Remarkably, epCSC number, BrdUpos myocytes
nd capillary density were significantly higher in IGF-1/
GF-treated pigs compared with CTRL (n  4) (Fig. 5A,
nline Fig. 10). Interestingly, at 2 months, BrdUpos myo-
yte maturation in the infarct region of treated pigs (diam-
ter  14.3  0.7 m) was increased compared with 21
ays (at 4 dose, 12.3  1.2 m, p  0.05), but they
ere still smaller than the average adult porcine myocyte
17  1 m, p  0.05). More importantly, infarct size,
s measured by computed planimetric analysis at sacrifice,
as significantly smaller in treated animals (16  4% of
he total left ventricular free wall) than in CTRL animals
24  2%, p  0.05).
The anatomical and histological improvement of cardiac
epair after MI in IGF-1/HGF-treated pigs was associated
Histological and Immunohistochemical Data 21Table 1 Histological and Immunohistochem
CTRL
(n  5
Fibrosis, % 36.2 5
Myocyte apoptosis, % 1.9 0
Myocyte hypertrophy, m 26 2
c-kitpos CSCs (border zone), % 0.4 0
c-kitpos CSCs (infarct area), % 0.7 0
c-kitposNkx2.5pos CSCs (border zone), % 0.2 0
c-kitposNkx2.5pos CSCs (infarct area), % 0.3 0
BrdUpos myocytes (infarct zone), % 0.5 0
BrdUpos myocytes (border area), % 1.2 0
Ki67pos myocytes (border zone), % 0.7 0
Ki67pos myocytes (infarct area), % 0.3 0
Number of capillaries, 0.2 m2 5 1
BrdUpos myocyte diameter* (infarct zone), m 6.4 1
*Diameter of normal BrdUneg myocyte  17  1 m; †p  0.05 v
IGF-1/HGF 2.
BrdU  bromodeoxyuridine; CSC  cardiac stem/progenitor c
MI  myocardial infarction.ith better LV function (Figs. 5B to 5F). Indeed, in the cTRL pigs, LV volumes and function progressively worsened
rom 72 h to 2 months after AMI, whereas IGF-1/HGF
revented LV cardiac dilation, which resulted in a better LV
jection fraction (45 8% vs. 33 6%, p 0.05) at 2 months
fter AMI (Figs. 5B to 5F, Online Table 1).
iscussion
ince its birth, regenerative cardiology’s holy grail has
een the development of procedures to either replace lost
yocytes with transplanted stem cells or to use stem cells
o mediate functional repair through paracrine effects
2,4,5,12,13). Although the discovery of eCSCs together
ith definitive proof of adult mammalian myocyte renewal
ere initially met with enthusiasm (14), mounting skepti-
ism has developed about the physiological significance and
egenerative potential of the resident c-kitpos eCSC popu-
lation (3,15,16). A recent report claimed that the cardio-
genic potential in vitro of the c-kitpos cardiac ells is robust
nly during neonatal age, but it is severely limited or lost in
he adult (17).
Undoubtedly, resident adult stem-progenitor cells are
ore abundant in early post-natal life and decline thereafter
18). These progenitor cells are highly active in the neonatal
eriod because they are main participants in the myocar-
ium hyperplastic growth and maturation to adulthood. In
ontrast, most eCSCs in the adult myocardium are quies-
ent (2). This difference might explain why eCSCs from the
dult have a higher threshold than those from the neonate
o activate their myogenic pathway in co-culture with fetal
ardiomyocytes (17). Moreover, isolated c-kitpos cardiac
cells are a mixed population containing not only real eCSCs
and progenitor/precursors but also cells committed to other
lineages, including mast cells. Indeed, we show that the
adult c-kitposCD45neg fraction is enriched for cells with
After MIata 21 Days After MI
IGF-1/HGF 1
(n  4)
IGF-1/HGF 2
(n  5)
IGF-1/HGF 4
(n  4)
26 7.0† 23 7.0† 16 2.5†‡
1.3 0.2† 0.9 0.15†‡ 0.4 0.1†‡§
23 1.2† 19 1.3† 16.5 1.1†‡
0.8 0.2† 1.2 0.1†‡ 1.7 0.3†‡§
1.3 0.2† 2.3 0.3†‡ 4.3 0.4†‡§
0.5 0.0† 0.7 0.1†‡ 0.9 0.05†‡§
0.9 0.2† 1.7 0.3†‡ 3.0 0.4†‡§
7.1 0.8† 12.7 1.5†‡ 19.3 2.6†‡§
5.4 0.6† 9.2 1.3†‡ 11.8 1.0†‡§
3.3 0.3† 4.7 0.4†‡ 6.5 0.9†‡§
3.9 0.6† 8.2 0.6†‡ 10.4 1.1†‡§
7 1 9 2† 11 1†‡§
9.2 1.3 10.4 1.5† 12.3 1.2†
ontrol (CTRL); ‡p  0.05 versus IGF-1/HGF 1; §p  0.05 versus
F  hepatocyte growth factor; IGF  insulin-like growth factor;Daysical D
)
.9
.25
.2
.1
.1
.1
.1
.1
.3
.2
.0
.2
ersus cardiac stem and progenitor cell properties, while the
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cells (data not shown). This is not different from bone
marrow stem cells, whereby only a very small fraction of
Figure 4 IGF-1/HGF Intracoronary Administration Induces Myoc
(A, B) Small, newly formed bromodeoxyuridine (BrdUpos) (green) myocytes (red) (
growth factor (HGF) of (A) 1 and (B) 4 treated pig hearts. (C) Within these reg
formed small BrdUpos myocytes (red) (-sarcomeric actin) in the border zone after
in the border zone after IGF-1/HGF-injection. (G) A small Ki67pos (green) mitotic m
All scale bars  20 m. (H, I) BrdUpos and Ki67pos myocyte number. Open bars in
and capillary structures: BrdU  green; -smooth muscle actin (SMA)  white; m
infarcted region of IGF-1/HGF 4 treated pig hearts. Bar  20 m. (L) Number of
IGF-1/HGF 1, 2, and 4, respectively. *p  0.05 versus CTRL; †p  0.05 ve
infarction.c-kitpos cells are actually stem/progenitor cells (18). Thus, itis not surprising that when the identity and number of true
stem/progenitor cells is not known, as in Zaruba et al. (17),
such undefined cell mixtures produce uninterpretable results
l Regeneration After AMI
meric actin) in the infarct regions of insulin-like growth factor (IGF)-1/hepatocyte
ting bands were small Ki67pos (green) proliferating myocytes. (D, E) Newly
HGF (D) 1 and (E) 4 doses. (F) Small Ki67pos myocytes were also present
precursor. Nuclei were stained by 4’,6-diamidino-2-phenylindole (DAPI) in blue.
border region; solid bars indicate infarct region. (J, K) Newly formed arterial
eavy chain (MHC)  red; von Willebrand factor (vWF)  red; DAPI  blue in the
aries in the infarct zone. All data are mean  SD; n  5, 4, 5, and 4 for CTRL,
F-1/HGF 1; ‡p  0.05 versus IGF-1/HGF 2. AMI  acute myocardialardia
-sarco
enera
IGF-1/
yocyte
dicate
yosin h
capill
rsus IGin vitro and even more so in vivo. Furthermore, the failure
u
t
s
s
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August 23, 2011:977–86 CSC Activation by IGF-1/HGF for Heart Regenerationof adult c-kitpos cells to differentiate in Zaruba et al. (17)
nlikely arises from their lack of actual regenerative poten-
ial but rather from the lack of effective protocols to
timulate their differentiation. Accordingly, the data pre-
ented here on the effects of IGF-1/HGF on adult c-kitpos
epCSCs activation, differentiation and maturation in vivo
and in vitro, further ascertains the role of these cells in
myocardial cell homeostasis and regeneration.
There is little controversy that the best replacement for
the lost myocardium after MI is functional autologous
myocardial tissue. However, as presently practiced, the
isolation and expansion of eCSCs for autologous cell trans-
plantation is slow, expensive, and of uneven quality (2). For
that reason, it is unlikely that autologous eCSCs transplan-
tation will ever become widely available to treat acute and
subacute MI (2,19). Even for late and chronic MI, autolo-
gous eCSCs can become available only to a very small
fraction of patients in need of myocardial regeneration and
at very high costs. Thus, there is need for strategies to
specifically activate in situ the intrinsic cardiac regenerative
Figure 5 IGF-1/HGF Intracoronary Administration Improves Car
(A) Number of c-kitpos endogenous porcine cardiac stem/progenitor cells (epCSCs
infarction (AMI). *p  0.05 versus control (CTRL). (B to D) Left ventricular end-dia
ejection fraction (LVEF) in the 2 groups of pigs. *p  0.05 versus 72 h; #p  0.0
gressive cardiac enlargement in CTRL as opposed to insulin-like growth factor (IGF
and n  5 for IGF-1/HGF 4.potential represented by the resident eCSCs using combi-nations of growth factors, cytokines, and drugs, obviating
the need for cell transplantation (2,19).
Recently, some growth factors/receptors axis—and acti-
vating small molecules—modulating CSCs fate have been
described (20,21). Indeed, eCSCs possess IGF-1 and HGF
signaling pathways that regulate their growth, survival, and
migration (7,8,22). Also, HGF induces expression of
cardiac-specific markers in embryonic stem cells (23).
Despite their value as proof of concept, the extrapolation
of murine and dog data (7,8) to the human pathology is
debatable. The 3 orders of magnitude difference in heart size
between mice and humans and the abundance of collaterals
in the dog coronary circulation make these experimental
infarct models not comparable to that of the human. More
importantly, in the mouse and canine studies, the growth
factors have been injected transepicardially through open-
chest surgery, which is not a suitable option in the treatment
of AMI. In contrast, the protocol used here could easily be
applied at the time of primary revascularization for AMI.
Six major conclusions emanate from this study: 1) the adult
Function After AMI
bromodeoxyuridine-positive (BrdUpos) myocytes 2 months after acute myocardial
volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular
us CTRL. (E, F) Cardiac magnetic resonance imaging (cMRI) images showing pro-
patocyte growth factor (HGF) treatment. All data are mean  SD; n  4 for CTRLdiac
) and
stolic
5 vers
)-1/heporcine myocardium harbors epCSCs—phenotypically distin-
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myocytes, a process specifically stimulated by HGF;
2) injection of small amounts of IGF-1/HGF in the
coronary artery supplying the infarcted region improves
cardiomyocyte survival and remodeling; it has significant
protective effect on myocardial tissue organization and
structure; 3) intracoronary IGF-1/HGF administration ac-
tivates the resident epCSCs, which multiply and differen-
tiate, fostering the regeneration of the myocytes and micro-
vasculature lost by the AMI; 4) the intensity of epCSC
activation, myocardial survival, and cell regeneration are
directly correlated to the dose of IGF-1/HGF administered,
strongly pointing to a direct cause-effect relationship; 5) the
effects of a single administration of IGF-1/HGF is still
measurable 2 months after its application, suggesting the
existence of a feedback loop triggered by the external stimuli
that activates the production of growth and survival factors
by the targeted cells, which explains the persistence and long
duration of the regenerative myocardial response; and 6)
IGF-1/HGF treatment improves cardiac function by de-
creasing cell death, infarct size, and preventing LV cardiac
dilation, resulting in better LV ejection fraction at 2 months
after AMI, as measured by cMRI.
Taken together, these results provide the proof of
concept needed to justify further experimental develop-
ment and refinement of this approach, which ultimately
could lead to an effective, simple, clinically applicable,
and widely available protocol of myocardial regeneration.
Study limitations. By extrapolation from fetal myocytes
24), it is likely that, despite the large number and progressive
aturation of the regenerated myocytes from 21 days to 2
onths, these immature myocytes have limited force-
enerating capacity when compared with the adult surviving
ounterparts. Therefore, the documented beneficial effect of
GF-1/HGF on ventricular performance is unlikely due only
o the direct force-generating contribution of the regenerated
yocytes. Most probably, the effects on ventricular perfor-
ance shown in Figure 5 are due to a combination of better
reservation of myocardial architecture, decreased myocyte
eath, reduced remodeling, and regeneration of new myocar-
ial cells including neomyogenesis as well neoangiogenesis. For
urther progress, the identification of the factors that drive full
SC-derived cardiomyocyte maturation is warranted.
Reprint requests and correspondence: Dr. Bernardo Nadal-
Ginard, The Stem Cell and Regenerative Biology Unit (BioStem),
RISES, Liverpool John Moores University, Tom Reilly Building,
Room 1.41, Byrom Street, Liverpool L3 3AF, United Kingdom.
E-mail: b.nadalginard@ljmu.ac.uk. OR Dr. Daniele Torella, Mo-
lecular and Cellular Cardiology, Department of Experimental and
Clinical Medicine, Magna Graecia University, Campus S.Venuta,
Viale Europa, 88100 Catanzaro, Italy. E-mail: dtorella@unicz.it.
REFERENCES1. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are
multipotent and support myocardial regeneration. Cell 2003;114:763–76.2. Torella D, Ellison GM, Karakikes I, Nadal-Ginard B. Resident
cardiac stem cells. Cell Mol Life Sci 2007;64:661–73.
3. Martin-Puig S, Wang Z, Chien KR. Lives of a heart cell: tracing the
origins of cardiac progenitors. Cell Stem Cell 2008;2:320–31.
4. Ellison GM, Torella D, Karakikes I, Nadal-Ginard B. Myocyte death
and renewal: modern concepts of cardiac cellular homeostasis. Nat
Clin Pract Cardiovasc Med 2007;4 Suppl 1:52–9.
5. Janssens S. Stem cells in the treatment of heart disease. Annu Rev Med
2010;61:287–300.
6. Terzic A, Nelson TJ. Regenerative medicine advancing health care
2020. J Am Coll Cardiol 2010;55:2254–7.
7. Urbanek K, Rota M, Cascapera S, et al. Cardiac stem cells possess
growth factor-receptor systems that after activation regenerate the
infarcted myocardium, improving ventricular function and long-term
survival. Circ Res 2005;97:663–73.
8. Linke A, Müller P, Nurzynska D, et al. Stem cells in the dog heart are
self-renewing, clonogenic, and multipotent and regenerate infarcted
myocardium, improving cardiac function. Proc Natl Acad Sci U S A
2005;102:8966–71.
9. Sperr WR, Bankl HC, Mundigler G, et al. The human cardiac mast
cell: localization, isolation, phenotype, and functional characterization.
Blood 1994;84:3876–84.
0. de Prado AP, Cuellas-Ramo´n C, Regueiro-Purriños M, et al. Closed-
chest experimental porcine model of acute myocardial infarction-
reperfusion. J Pharmacol Toxicol Meth 2009;60:301–6.
1. Behfar A, Perez-Terzic C, Faustino RS, et al. Cardiopoietic program-
ming of embryonic stem cells for tumor-free heart repair. J Exp Med
2007;204:405–20.
2. Kubal C, Sheth K, Nadal-Ginard B, Galiñanes M. Bone marrow cells
have a potent anti-ischemic effect against myocardial cell death in man.
J Thorac Cardiovasc Surg 2006;132:1112–8.
3. Lai VK, Linares-Palomino J, Nadal-Ginard B, Galiñanes M. Bone
marrow cell-induced protection of the human myocardial: character-
ization and mechanism of action. J Thorac Cardiovasc Surg 2009;138:
1400–8.
4. Leinwand LA. Hope for a broken heart? Cell 2003;114:658–9.
5. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy
and lessons from the heart. Nature 2008;453:322–9.
6. Pouly J, Bruneval P, Mandet C, et al. Cardiac stem cells in the real
world. J Thorac Cardiovasc Surg 2008;135:673–8.
7. Zaruba MM, Soonpaa M, Reuter S, Field LJ. Cardiomyogenic
potential of C-kit()-expressing cells derived from neonatal and adult
mouse hearts. Circulation 2010;121:1992–2000.
8. Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways
to aging and cancer. Cell 2008:132;681–96.
9. Nadal-Ginard B, Torella D, Ellison G. Cardiovascular regenerative
medicine at the crossroads. Clinical trials of cellular therapy must now
be based on reliable experimental data from animals with characteris-
tics similar to human’s. Rev Esp Cardiol 2006:59;1175–89.
0. Sadek H, Hannack B, Choe E, et al. Cardiogenic small molecules that
enhance myocardial repair by stem cells. Proc Natl Acad Sci U S A
2008;105:6063–8.
1. Engel FB, Hsieh PC, Lee RT, Keating MT. FGF1/p38 MAP kinase
inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and
rescues function after myocardial infarction. Proc Natl Acad Sci U S A
2006;103:15546–51.
2. Torella D, Rota M, Nurzynska D, et al. Cardiac stem cell and myocyte
aging, heart failure, and insulin-like growth factor-1 overexpression.
Circ Res 2004;94:514–24.
3. Roggia C, Ukena C, Böhm M, Kilter H. Hepatocyte growth factor
(HGF) enhances cardiac commitment of differentiating embryonic
stem cells by activating PI3 kinase. Exp Cell Res 2007;313:921–30.
4. Siedner S, Krüger M, Schroeter M, et al. Developmental changes in
contractility and sarcomeric proteins from the early embryonic to the
adult stage in the mouse heart. J Physiol 2003;548:493–505.
Key Words: cardiac magnetic resonance imaging y cardiac stem cells y
rowth factors y myocardial infarction y myocardial regeneration.
APPENDIX
For a complete description of Methods, supplementary figures, a supple-
mentary table, and a supplementary video, please see the online version of
this article.
